Karyopharm Therapeutics, Inc. Forecast, price target & analysts
Karyopharm Therapeutics, Inc. Target price 2026 - Analyst rating & recommendation
Karyopharm Therapeutics, Inc. Classifications & Recommendation
Karyopharm Therapeutics, Inc. Price Target
| Target Price | $7.65 |
| Price | $1.62 |
| Potential |
372.22%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Karyopharm Therapeutics, Inc. 2027 .
The average Karyopharm Therapeutics, Inc. target price is $7.65.
This is
372.22%
register free of charge
$11.55
612.96%
register free of charge
$3.03
87.04%
register free of charge
|
|
| A rating was issued by 11 analysts: 9 Analysts recommend Karyopharm Therapeutics, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Karyopharm Therapeutics, Inc. stock has an average upside potential 2027 of
372.22%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 146.07 | 136.08 |
| 0.57% | 6.84% | |
| Net Margin | -134.21% | -73.71% |
| 155.07% | 45.08% |
7 Analysts have issued a sales forecast Karyopharm Therapeutics, Inc. 2026 . The average Karyopharm Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
7 Karyopharm Therapeutics, Inc. Analysts have issued a net profit forecast 2026. The average Karyopharm Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -17.93 | -4.42 |
| 90.54% | 75.35% | |
| P/E | negative | |
| EV/Sales | 2.16 |
7 Analysts have issued a Karyopharm Therapeutics, Inc. forecast for earnings per share. The average Karyopharm Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Karyopharm Therapeutics, Inc....
Current Karyopharm Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jul 31 2026 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Jul 31 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 06 2026 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Apr 27 2026 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Mar 30 2026 |
| Baird |
Locked
➜
Locked
|
Locked | Mar 25 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 25 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jul 31 2026 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Jul 31 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 06 2026 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Apr 27 2026 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Mar 30 2026 |
|
Locked
Baird:
Locked
➜
Locked
|
Mar 25 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 25 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
